Edward B Reilly (Edward Reilly)

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 8

Top Topics

Tyrosine Kinase

Hodgkin Lymphoma

Magnetic Resonance

Top Venues

Clinical cancer research : an official journal of the American Association for Cancer Research

Molecular cancer therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Sonia Jain, Jessica I Griffith, Kendra A Porath, Sneha Rathi, Jiayan Le, Tugce I Pasa, Paul A Decker, Shiv K Gupta, Zeng Hu, Brett L Carlson, Katrina K Bakken, Danielle M Burgenske, Thomas M Feldsien, Didier R Lefebvre, Rachael Ann Vaubel, Jeanette E Eckel-Passow, Edward B Reilly, William F Elmquist, Jann N Sarkaria
Bystander Effects, Pharmacokinetics, and Linker-Payload Stability of EGFR-Targeting Antibody-Drug Conjugates Losatuxizumab Vedotin and Depatux-M in Glioblastoma Models. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (15) (2024)
Sonia Jain, Jessica I Griffith, Kendra A Porath, Sneha Rathi, Jiayan Le, Tugce I Pasa, Paul A Decker, Shiv K Gupta, Zeng Hu, Brett L Carlson, Katrina K Bakken, Danielle M Burgenske, Thomas M Feldsien, Didier R Lefebvre, Rachael Ann Vaubel, Jeanette E Eckel-Passow, Edward B Reilly, William F Elmquist, Jann N Sarkaria
Bystander Effects, Pharmacokinetics, and Linker-Payload Stability of EGFR-Targeting Antibody-Drug Conjugates Losatuxizumab Vedotin and Depatux-M in Glioblastoma Models. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (15) (2024)
Sonia Jain, Jessica I Griffith, Kendra A Porath, Sneha Rathi, Jiayan Le, Tugce I Pasa, Paul A Decker, Shiv K Gupta, Zeng Hu, Brett L Carlson, Katrina K Bakken, Danielle M Burgenske, Thomas M Feldsien, Didier R Lefebvre, Rachael Ann Vaubel, Jeanette E Eckel-Passow, Edward B Reilly, William F Elmquist, Jann N Sarkaria
Bystander effects, pharmacokinetics, and linker-payload stability of EGFR-targeting antibody-drug conjugates Losatuxizumab vedotin and Depatux-M in glioblastoma models. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Sonia Jain, Jessica I Griffith, Kendra A Porath, Sneha Rathi, Jiayan Le, Tugce I Pasa, Paul A Decker, Shiv K Gupta, Zeng Hu, Brett L Carlson, Katrina K Bakken, Danielle M Burgenske, Thomas M Feldsien, Didier R Lefebvre, Rachael Ann Vaubel, Jeanette E Eckel-Passow, Edward B Reilly, William F Elmquist, Jann N Sarkaria
Bystander Effects, Pharmacokinetics, and Linker-Payload Stability of EGFR-Targeting Antibody-Drug Conjugates Losatuxizumab Vedotin and Depatux-M in Glioblastoma Models. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (15) (2024)
Sonia Jain, Jessica I Griffith, Kendra A Porath, Sneha Rathi, Jiayan Le, Tugce I Pasa, Paul A Decker, Shiv K Gupta, Zeng Hu, Brett L Carlson, Katrina K Bakken, Danielle M Burgenske, Thomas M Feldsien, Didier R Lefebvre, Rachael Ann Vaubel, Jeanette E Eckel-Passow, Edward B Reilly, William F Elmquist, Jann N Sarkaria
Bystander Effects, Pharmacokinetics, and Linker-Payload Stability of EGFR-Targeting Antibody-Drug Conjugates Losatuxizumab Vedotin and Depatux-M in Glioblastoma Models. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (15) (2024)
Adam S Chervin, Jennifer D Stone, Iwona Konieczna, Kelly M Calabrese, Ningyan Wang, Dipica Haribhai, Feng Dong, Michael K White, Luis E Rodriguez, Gail T Bukofzer, Paul A Ellis, Cormac P Cosgrove, Claudie Hecquet, Jerry D Clarin, Joann P Palma, Edward B Reilly
ABBV-184: A novel survivin-specific TCR/CD3 bispecific T cell engager is active against both solid tumor and hematological malignancies. Molecular cancer therapeutics (2023)
Mark G Anderson, Hugh D Falls, Michael J Mitten, Anatol Oleksijew, Kedar S Vaidya, Erwin R Boghaert, Wenqing Gao, Joann P Palma, Diana Cao, Puey-Ling Chia, Thomas John, Hui Kong Gan, Andrew M Scott, Edward B Reilly
Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody-Drug Conjugate. Molecular cancer therapeutics 19 (10) (2020)
John H Strickler, Patricia LoRusso, Ravi Salgia, Yoon-Koo Kang, Chia Jui Yen, Chia-Chi Lin, Peter Ansell, Monica Motwani, Shekman Wong, Huibin Yue, Lan Wang, Edward B Reilly, Daniel Afar, Louie Naumovski, Ramesh K Ramanathan
Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti-c-Met Antibody, in Patients with Advanced Solid Tumors. Molecular cancer therapeutics 19 (5) (2020)